Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 163 member A (FAM163A)
- Target
- FAM163A
- Molecular classification
- Other
01
Overview
Family with sequence similarity 163 member A (FAM163A) is a secretory protein originally identified in neuroblastoma cell lines and predominantly expressed in the brain. It has roles in promoting cell proliferation—particularly in cancer—through direct interaction with ERK and 14-3-3β, activating the ERK signaling pathway. FAM163A is also involved in the regulation of mitochondrial dynamics and biogenesis in neurons, affecting hypothalamic neuron activity tied to metabolic control. Overexpression of FAM163A is associated with poor prognosis in some cancers, such as lung squamous cell carcinoma. Its biological functions remain incompletely characterized, but current research suggests relevance in cancer biology, neuronal metabolism, and mitochondrial regulation[1][2].
- Other names
- Neuroblastoma-derived secretory protein (NDSP)C1orf76cebelinMGC16664Protein FAM163A
02
Mechanism of action
Drugs such as MEK inhibitors (U0126) act by blocking the phosphorylation of ERK and downstream signaling potentiated by FAM163A[2].
03
Biological functions
Cell proliferationSignal transduction (ERK/MAPK pathway)Regulation of mitochondrial dynamics and biogenesisRegulation of neuronal activity, especially in hypothalamic neurons controlling metabolism
04
Disease associations
Cancer (neuroblastoma, lung squamous cell carcinoma[2])Central metabolic regulation (e.g., effects on food intake, hypothalamic function[1])
05
Safety considerations
None documented to date, as it is an experimental target with limited pharmacological development. Possible safety concerns may arise from potential off-target effects on neuronal mitochondrial function or broader metabolic impacts, but these are speculative and not reported in current literature[1].
06
Interacting drugs
U0126 (MEK inhibitor; studied experimentally to block FAM163A’s effect on ERK signaling[2])
07
Biomarkers
FAM163A expression is a prognostic biomarker for poor outcome in lung squamous cell carcinoma[2].Serum levels or tissue expression could be explored for patient stratification in neuroblastoma or other cancers.
Beyond the preview
Go deeper on Family with sequence similarity 163 member A (FAM163A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Family with sequence similarity 163 member A (FAM163A).